Payment overview · 2025
General Payments
$2,092.79
91 reported records · 24 companies
Healthcare provider profile · identity verified
Tejas I. Patel, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BURBANK, CA · NPI 1437125770
Verified facts
What the public records show
CMS Open Payments records show Tejas I. Patel, MD received $2,092.79 in general payments during 2025 across 91 reported records.
Novo Nordisk Inc accounted for 20.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 38 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Entresto, Jardiance, Mounjaro, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 349 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 201 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $426.82 | 20.4% | 22 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $213.54 | 10.2% | 8 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $209.53 | 10.0% | 9 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $177.28 | 8.5% | 8 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $170.47 | 8.2% | 7 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $162.25 | 7.8% | 9 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $137.09 | 6.5% | 3 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $125.89 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $111.09 | 5.3% | 5 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $45.08 | 2.1% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $42.89 | 2.0% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $35.41 | 1.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $32.96 | 1.6% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $31.08 | 1.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $28.02 | 1.3% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $19.13 | 0.9% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $17.63 | 0.8% | 1 | 2025 |
| Currax Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $15.93 | 0.8% | 1 | 2025 |
| Ionis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.90 | 0.8% | 1 | 2025 |
| BETA BIONICS, INC. | Unresolved — no canonical attribution shown | $15.69 | 0.8% | 1 | 2025 |
| Almatica Pharma LLC | Unresolved — no canonical attribution shown | $15.59 | 0.7% | 1 | 2025 |
| TOLMAR, INC. | Unresolved — no canonical attribution shown | $15.43 | 0.7% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.38 | 0.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $13.71 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,092.79 | 91 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $212.65 | 11 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $209.29 | 10 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $170.47 | 7 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $165.55 | 6 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $150.88 | 8 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $134.92 | 8 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $125.89 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $125.28 | 7 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $122.88 | 5 | 2025 |
Source payment records
|
|||||
| INSIGNIA Normalized: insignia |
Device | Stryker Corporation | $105.51 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $96.65 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $96.40 | 4 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $75.62 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $66.46 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $47.99 | 2 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $45.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $44.63 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $42.89 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $35.41 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| MAKO Normalized: mako |
Device | Stryker Corporation | $31.58 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $31.08 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $28.02 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $19.13 | 1 | 2025 |
Source payment records
|
|||||
| Saxenda Normalized: saxenda |
Drug | Novo Nordisk Inc | $18.47 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $17.63 | 1 | 2025 |
Source payment records
|
|||||
| CONTRAVE Normalized: contrave |
Drug | Currax Pharmaceuticals LLC | $15.93 | 1 | 2025 |
Source payment records
|
|||||
| TRYNGOLZA Normalized: tryngolza |
Drug | Ionis Pharmaceuticals, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| iLet Bionic Pancreas Normalized: ilet bionic pancreas |
Device | BETA BIONICS, INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Contact Detach Normalized: ilet insulin infusion kit contact detach |
Device | BETA BIONICS, INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| iLet Insulin Infusion Kit Inset Normalized: ilet insulin infusion kit inset |
Device | BETA BIONICS, INC. | $15.69 | 1 | 2025 |
Source payment records
|
|||||
| LOREEV XR Normalized: loreev xr |
Drug | Almatica Pharma LLC | $15.59 | 1 | 2025 |
Source payment records
|
|||||
| JATENZO Normalized: jatenzo |
Drug | TOLMAR, INC. | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.38 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $13.71 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 349 | exact normalized | Medicare Part D |
| ENTRESTO entresto |
2025 | Entresto | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 201 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 85 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 163 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 49 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
62 | 19 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 16 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 56 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
349 | 67 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
49 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
201 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
85 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
163 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1329 | 393 |
| Amlodipine Besylate | Amlodipine Besylate | 761 | 227 |
| Levothyroxine Sodium | Levothyroxine Sodium | 685 | 174 |
| Omeprazole | Omeprazole | 605 | 184 |
| Losartan Potassium | Losartan Potassium | 445 | 140 |
| Metformin Hcl | Metformin Hcl | 415 | 111 |
| Metoprolol Succinate | Metoprolol Succinate | 362 | 99 |
| Eliquis | Apixaban | 349 | 67 |
| Valsartan | Valsartan | 333 | 96 |
| Tamsulosin Hcl | Tamsulosin Hcl | 279 | 81 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 274 | 81 |
| Pantoprazole Sodium | Pantoprazole Sodium | 273 | 82 |
| Gabapentin | Gabapentin | 264 | 72 |
| Lisinopril | Lisinopril | 262 | 78 |
| Escitalopram Oxalate | Escitalopram Oxalate | 247 | 72 |
| Hydrochlorothiazide | Hydrochlorothiazide | 216 | 70 |
| Alprazolam | Alprazolam | 205 | 65 |
| Furosemide | Furosemide | 205 | 70 |
| Jardiance | Empagliflozin | 201 | 56 |
| Trazodone Hcl | Trazodone Hcl | 199 | 57 |
| Simvastatin | Simvastatin | 193 | 51 |
| Azithromycin | Azithromycin | 191 | 156 |
| Alendronate Sodium | Alendronate Sodium | 183 | 59 |
| Zolpidem Tartrate | Zolpidem Tartrate | 177 | 49 |
| Pravastatin Sodium | Pravastatin Sodium | 164 | 41 |
| Ozempic | Semaglutide | 163 | 41 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 141 | 36 |
| Januvia | Sitagliptin Phosphate | 137 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 136 | 41 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 135 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 135 | 33 |
| Carvedilol | Carvedilol | 132 | 49 |
| Sertraline Hcl | Sertraline Hcl | 132 | 29 |
| Metformin Hcl Er | Metformin Hcl | 128 | 40 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 121 | 25 |
| Tramadol Hcl | Tramadol Hcl | 116 | 48 |
| Allopurinol | Allopurinol | 115 | 32 |
| Pioglitazone Hcl | Pioglitazone Hcl | 115 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 110 | 31 |
| Montelukast Sodium | Montelukast Sodium | 110 | 32 |
| Lorazepam | Lorazepam | 105 | 40 |
| Methylprednisolone | Methylprednisolone | 103 | 93 |
| Prednisone | Prednisone | 98 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 97 | 77 |
| Levetiracetam | Levetiracetam | 95 | 27 |
| Fluticasone Propionate | Fluticasone Propionate | 94 | 33 |
| Potassium Chloride | Potassium Chloride | 92 | 26 |
| Glimepiride | Glimepiride | 91 | 23 |
| Glipizide | Glipizide | 88 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 87 | 24 |
| Mounjaro | Tirzepatide | 85 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 81 | 17 |
| Donepezil Hcl | Donepezil Hcl | 80 | 18 |
| Meloxicam | Meloxicam | 74 | 24 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 73 | 41 |
| Levofloxacin | Levofloxacin | 72 | 63 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 20 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 64 | 59 |
| Mirtazapine | Mirtazapine | 64 | 15 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 64 | 20 |
| Ezetimibe | Ezetimibe | 63 | 24 |
| Valacyclovir | Valacyclovir Hcl | 63 | 27 |
| Atenolol | Atenolol | 62 | 16 |
| Synthroid | Levothyroxine Sodium | 62 | 19 |
| Finasteride | Finasteride | 61 | 16 |
| Ibuprofen | Ibuprofen | 61 | 29 |
| Memantine Hcl | Memantine Hcl | 60 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 60 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 59 | 18 |
| Cephalexin | Cephalexin | 58 | 53 |
| Bupropion Xl | Bupropion Hcl | 56 | 18 |
| Clonazepam | Clonazepam | 56 | 14 |
| Amiodarone Hcl | Amiodarone Hcl | 54 | 15 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 54 | 34 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 46 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 53 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 52 | suppressed |
| Diazepam | Diazepam | 51 | 11 |
| Clonidine Hcl | Clonidine Hcl | 50 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | 16 |
| Myrbetriq | Mirabegron | 48 | 13 |
| Naproxen | Naproxen | 48 | 29 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 48 | 12 |
| Spironolactone | Spironolactone | 48 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 47 | 27 |
| Bumetanide | Bumetanide | 46 | 12 |
| Hydralazine Hcl | Hydralazine Hcl | 46 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 46 | 14 |
| Diclofenac Sodium | Diclofenac Sodium | 44 | 15 |
| Dutasteride | Dutasteride | 44 | suppressed |
| Hydrocortisone | Hydrocortisone | 44 | 21 |
| Famotidine | Famotidine | 43 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | 14 |
| Meclizine Hcl | Meclizine Hcl | 43 | 21 |
| Xarelto | Rivaroxaban | 42 | 12 |
| Brilinta | Ticagrelor | 41 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 41 | 14 |
| Paxlovid | Nirmatrelvir/Ritonavir | 40 | 40 |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Lidocaine | Lidocaine | 38 | 12 |
| Mupirocin | Mupirocin | 37 | 15 |
| Divalproex Sodium | Divalproex Sodium | 35 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 35 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 32 | 11 |
| Farxiga | Dapagliflozin Propanediol | 32 | suppressed |
| Tradjenta | Linagliptin | 32 | suppressed |
| Ketoconazole | Ketoconazole | 31 | 11 |
| Trulicity | Dulaglutide | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | 11 |
| Doxazosin Mesylate | Doxazosin Mesylate | 30 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 30 | 12 |
| Lansoprazole | Lansoprazole | 30 | 11 |
| Temazepam | Temazepam | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 27 | 17 |
| Dexlansoprazole Dr | Dexlansoprazole | 27 | suppressed |
| Testosterone | Testosterone | 27 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Latanoprost | Latanoprost | 25 | suppressed |
| Primidone | Primidone | 25 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 24 | suppressed |
| Prolia | Denosumab | 24 | 16 |
| Sucralfate | Sucralfate | 24 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 23 | suppressed |
| Nystatin | Nystatin | 23 | 14 |
| Irbesartan | Irbesartan | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Methotrexate | Methotrexate Sodium | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Entresto | Sacubitril/Valsartan | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 15 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 20 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 20 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Pregabalin | Pregabalin | 19 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 19 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 18 | suppressed |
| Carisoprodol | Carisoprodol | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 18 | 16 |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Fenofibrate | Fenofibrate | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 17 |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 16 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | 12 |
| Olanzapine | Olanzapine | 16 | suppressed |
| Premarin | Estrogens, Conjugated | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Acetazolamide | Acetazolamide | 15 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 15 | suppressed |
| Amoxicillin | Amoxicillin | 14 | 11 |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Cefdinir | Cefdinir | 14 | 14 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Fluocinonide | Fluocinonide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Lovastatin | Lovastatin | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 13 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Glyburide | Glyburide | 13 | suppressed |
| Levemir Flexpen | Insulin Detemir | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Vascepa | Icosapent Ethyl | 13 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 12 | suppressed |
| Letrozole | Letrozole | 12 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 12 | 12 |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Zetia | Ezetimibe | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 11 | suppressed |
| Lyumjev Kwikpen U-100 | Insulin Lispro-Aabc | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 11 | suppressed |
| Vraylar | Cariprazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,092.79 · 91 records | Novo Nordisk Inc | AIRSUPRA, APRETUDE, AREXVY, BREZTRI, CONTRAVE, Dexcom G6 Transmitter, ELIQUIS, ENTRESTO, EVENITY, FREESTYLE LIBRE 3, INSIGNIA, JARDIANCE, JATENZO, Kerendia, Korlym, LEQVIO, LOREEV XR, MAKO, MOUNJARO, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, SHINGRIX, Saxenda, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TRELEGY ELLIPTA, TRYNGOLZA, TZIELD, UBRELVY, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE, iLet Bionic Pancreas, iLet Insulin Infusion Kit Contact Detach, iLet Insulin Infusion Kit Inset | 15 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error